Phio Pharmaceuticals Reports Strong Phase 1b PH-762 Data with 70% ORR and Favorable Safety in Skin Cancer Trial

summarizeSummary

Phio Pharmaceuticals reported positive Phase 1b clinical trial results for PH-762 in skin cancer, showing a 70% overall response rate for squamous cell carcinomas with high complete clearance rates and a favorable safety profile.

check_boxKey Events

• Positive Phase 1b Clinical Trial Results

  The company announced key tumor response data from all cohorts in its intratumoral PH-762 dose escalation cutaneous carcinoma trial.

• High Overall Response Rate (ORR)

  Pathology data indicated a 70% overall response rate for squamous cell carcinomas (cSCC), with 10 of 14 responders reporting 100% clearance.

• Favorable Safety and Tolerability

  PH-762 demonstrated favorable safety and tolerability at all dose escalations, with no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects.

• Advancing Clinical Development

  CEO Robert Bitterman stated that the company is now actively designing the follow-on clinical trial, marking the next step in the regulatory development pathway.

auto_awesomeAnalysis

Phio Pharmaceuticals announced compelling Phase 1b clinical trial data for its lead compound, PH-762, in cutaneous carcinomas. The reported 70% overall response rate for squamous cell carcinomas, with 10 out of 14 responders achieving 100% clearance, is a significant positive signal for an early-stage trial. The favorable safety and tolerability profile across all dose escalations further de-risks the program. This data provides strong validation for the company's INTASYL® gene silencing technology and supports progression to the next stages of clinical development, which is critical for a clinical-stage biopharmaceutical company.